drug · small molecule
SELEXIPAG
Marketedupdated 5mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.
targets
Prostacyclin receptor
all catalysts(1)
Trials studying SELEXIPAG
- phase3A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
- phase2Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
- phase2A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
- phase3A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
- —Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
- phase3Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
- phase3Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
- phase1A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 31, 2026
32 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (104)
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10821108*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Jun 1, 2037patentUS 10828298*PED
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10821108
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Dec 1, 2036formulationUS 10828298
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Feb 1, 2031patentUS 8791122*PED4.3y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Dec 25, 2030patentUS 9284280*PED4.2y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Aug 1, 2030compositionUS 87911223.8y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Jun 25, 2030method-of-use (U-1831)US 92842803.7y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Feb 12, 2030patentUS 9173881*PED3.4y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Aug 12, 2029method-of-use (U-1798)US 91738812.9y
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Apr 30, 2027patentUS 7205302*PED213d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
- Oct 31, 2026compositionUS 720530232d
News(1)
- After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaborationAfter signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that